SCHEMBL4477428

SCHEMBL4477428

CCN1CCN(Cc2ccc(-c3cc(C)ccc3Cl)cc2)CC1c1ccccc1

nearest known ligand 0.64

Predicted protein targets (top 12)

geneUniProtsupporting neighboursconfidence
CNR2 P34972 4/20 0.64
P2RX7 Q99572 2/20 0.44
LMNA P02545 1/20 0.41
POLB P06746 1/20 0.41
NR1H2 P55055 2/20 0.41
NR1H3 Q13133 1/20 0.41
SIGMAR1 Q99720 3/20 0.39
ALDH1A1 P00352 1/20 0.39
CYP46A1 Q9Y6A2 1/20 0.38
S1PR1 P21453 1/20 0.38
S1PR5 Q9H228 1/20 0.38
DRD4 P21917 1/20 0.38

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4476194 0.88 CNR2 (0.58) CNR2P2RX7SIGMAR1S1PR1S1PR5
SCHEMBL4472224 0.87 CNR2 (0.66) CNR2P2RX7LMNAPOLBSIGMAR1
SCHEMBL4649711 0.87 CNR2 (0.56) CNR2P2RX7LMNAPOLBNR1H2
SCHEMBL4473540 0.84 CNR2 (0.57) CNR2LMNAPOLBSIGMAR1ALDH1A1
SCHEMBL4482477 0.84 CNR2 (0.63) CNR2LMNAPOLBSIGMAR1ALDH1A1
SCHEMBL4473536 0.84 CNR2 (0.57) CNR2LMNAPOLBSIGMAR1ALDH1A1
SCHEMBL14495607 0.84 CNR2 (0.63) CNR2LMNAPOLBSIGMAR1ALDH1A1
SCHEMBL27489861 0.83 P2RX7 (0.50) CNR2P2RX7LMNANR1H2NR1H3
SCHEMBL4481910 0.83 CNR2 (0.61) CNR2P2RX7ALDH1A1CYP46A1S1PR1
SCHEMBL4694748 0.83 CNR2 (0.46) CNR2P2RX7LMNANR1H2NR1H3

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7595397-B2 Compounds which modulate the CB2 receptor BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) 2009-09-29 US disclosed
US-7595397-B2 Compounds which modulate the CB2 receptor BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) 2009-09-29 US disclosed
US-7595397-B2 Compounds which modulate the CB2 receptor BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) 2009-09-29 US disclosed
US-20070191340-A1 Compounds Which Modulate The CB2 Receptor BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) 2007-08-16 US disclosed
US-20070191340-A1 Compounds Which Modulate The CB2 Receptor BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) 2007-08-16 US disclosed
US-20070191340-A1 Compounds Which Modulate The CB2 Receptor BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) 2007-08-16 US disclosed
WO-2007070760-A2 COMPOUNDS WHICH MODULATE THE CB2 RECEPTOR BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) 2007-06-21 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20070191340-A1 Compounds Which Modulate The CB2 Receptor CNR1, CNR2, ARRB1 CNR2 2/4885P2RX7 196/4885LMNA 3602/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.